| Name | Title | Contact Details |
|---|---|---|
Tina Schmucker |
CTE Director at Pathways | Profile |
The Faulkner Organization is a family-owned automotive dealership group based in Pennsylvania, founded in 1932. With a legacy of over nine decades, it operates 31 dealerships across Central and Southeastern Pennsylvania, representing 22 vehicle brands. The company specializes in the sale and service of new and pre-owned vehicles. Their offerings include automotive sales, maintenance and repair services, financing and insurance assistance, genuine parts supply, and body shop repair services. The Faulkner Organization is committed to customer satisfaction, employee development, and maintaining high ethical standards in all business dealings.
SCC was originally founded in 2006, and initially conceived as a direct marketing arm for dealerships. Distinguishing itself by offering premium plans directly to consumers underwritten by A-rated insurers, SCC helps car owners find the right vehicle protection plans within their budget. Our VSC (Vehicle Service Contract) agents walk consumers through the many options available to help navigate the extended auto warranty landscape. Our mission at Secure Car Care is to help you have a better car repair experience by finding the best protection plan for you and your vehicle.
NFW is a circularity platform for plastic-free performance materials. NFW follows three Ground Rules in everything we develop: start well, stay clean, end well. While nearly everything in the built world relies on some type of plastic that began as crude oil and that will become plastic pollution, we are establishing a new material reality. We believe all materials should begin and end as nutrients, ready for the next growth cycle—true circularity. Our multi-material platform serves a wide range of industries—from fashion and footwear to automotive and upholstery. NFW technology embeds seamlessly into existing supply chains, enabling the worlds most iconic brands to design and scale products with high-performance, plastic-free materials. NFW makes global brands more sustainable, empowering them to create without plastics. Alongside the boldest brands and visionary designers, we are pioneering a naturally circular, post-oil economy.
GKN Powder Metallurgy is the global leader in powder metal solutions, shaping the future with sustainable metal technologies that drive innovation and performance in the automotive and other industries. With a global manufacturing network comprised of 28 manufacturing facilities and 2 innovation centers across 9 countries, we produce 10 million high precision powder metal components daily and 250,000 tons of atomized metal powder per year. Our portfolio of advanced process technologies includes conventional PM for cost-effective, high-volume production; MIM (Metal Injection Molding) for complex, lightweight parts; powder forging for enhanced durability; aluminum PM for lightweight components; and metal additive manufacturing for innovative designs and scalable production. We provide solutions that enable electrification, including manufacturing custom parts for e-motors, e-drivetrains, magnets, batteries, drive-by-wire, and thermal management systems. Our collaborative approach allows us to develop tailor-made solutions that perfectly match your application and deliver superior performance, efficiency, and reduced weight. Sustainability is at the core of who we are. All our metal powders are made from 100% recyclable scrap metal and are designed with the circular economy in mind. Our dedication to combating climate change, minimizing waste, and upholding the highest social responsibility standards has earned us the EcoVadis Platinum medal - an award for excellence in ESG performance given only to the top 1% of companies globally. At GKN Powder Metallurgy, we are not just about manufacturing; we are about technology that impacts the world. Join us as we continue to lead, innovate, and shape the future of manufacturing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.